Development of Key Technologies for Real-Time Diagnosis, Surveillance and Interventionof Resistant-Bacterial Infections Based on Nanopore Sequencing

基于纳米孔测序的耐药细菌感染实时诊断、监测和干预关键技术研究进展

• 批准号: 104991
• 金额: $ 81.81万
• 依托单位: OPPILOTECH LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104991
• 关键词: Development; Key; Technologies; Real; Time

The proposed project aims to tackle two of the major hurdles in the fight against AMR, new drugs and newdiagnostics. The new diagnostics will utilise cutting edge UK technology (Oxford Nanopore sequencing) toprovide test results with unprecedented depth of information within 6 hours as opposed to the currenttechnologies which routinely take 24-48 hours. The approach to new drugs entails developing "Potentiators" -agents that can permeabilise the cell wall of bacteria allowing the use of established antibacterial compounds.The Potentiators in this project target Gram-negative (OPT-200) and Gram-positive (OPT-1) bacteria and bothhave novel modes of actions representing first-in-class antibacterial programmes. The focus of this project willbe on Hospital Acquired Pneumonia (HAP) and subset of HAP Ventilator Acquired Pneumonia (VAP). HAP/VAPare important infections throughout the world and are a major cause of morbidity, mortality and increases inhospital stay resulting in escalation of healthcare costs. The long-term goals of this project are to provide rapiddiagnosis technology for HAP/VAP that can be combined with a potentiator treatment regime.Finance Summary Table – How to complete this section

拟议中的项目旨在解决对抗抗菌素耐药性的两个主要障碍：新药和新诊断方法。新的诊断方法将利用英国最先进的技术（牛津纳米孔测序），在6小时内提供前所未有的信息深度的测试结果，而不是目前的技术通常需要24-48小时。开发新药的方法需要开发“增强剂”——一种能够渗透细菌细胞壁的药剂，使已有的抗菌化合物得以使用。该项目的增效剂针对革兰氏阴性（OPT-200）和革兰氏阳性（OPT-1）细菌，两者都具有新颖的作用模式，代表了一流的抗菌方案。本项目将重点研究医院获得性肺炎（HAP）及其呼吸机获得性肺炎（VAP）亚型。HAP/ vapa是世界各地的重要感染，是发病率、死亡率和住院时间增加的主要原因，导致医疗费用上升。该项目的长期目标是提供HAP/VAP的快速诊断技术，该技术可与增强剂治疗方案相结合。财务汇总表-如何完成本节